Baxter International Inc. · NYSE:BAX
Baxter International — Investor Day (May 2018)
16 slides from Baxter International's investor day presentation, May 21, 2018
Slide 1: Pharmaceuticals
PHARMACEUTICALS Brik Brik Eyre Eyre President, Americas SVP and President, Americas May 21, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter’s financial results, R&D pipeline, including planned product launches (many of which are subject to regulatory approval) and results of clinical trials, business development activities, capital structure, c
Slide 3: Generic Pharmaceuticals Market Overview
Generic Pharmaceuticals Market Overview1 Global Market Size Inhaled Anesthesia CAGR2 ~$77B Inhaled gases used in surgeries #1 (2%) – (3%) Globally ~$57B 4% - 5% Drug Compounding Preparing individual pharmaceutical doses for #1-2 Baxter in Markets 6% - 7% Addressable hospital patients Served Baxter M
Slide 4: Baxter Addressable Market Over The LRP
Baxter Addressable Market Over The LRP $22B >2x More than doubling the size of Baxter’s $10B addressable market 2018 Baxter Portfolio1 2023 71 molecules 138 molecules 67 NEW molecules ~130 products ~240 products ~110 NEW products ~1,900 registrations ~2,800 registrations ~900 NEW registrations Addre
Slide 5: Generic Injectable Market Dynamics
Generic Injectable Market Dynamics1 Hospital Cost Generic Molecule Pressures Growth 80% of hospital patients ~$6B of branded injectable globally prescribed generic patent expirations in the U.S. injectables over the next 5 years Supply Continuity Regulatory Challenges Compliance 95 products are curr
Slide 6: Baxter Pharmaceuticals Portfolio
Baxter Pharmaceuticals Portfolio Inhaled Anesthesia Generic Injectable Drugs Sevoflurane 86% Differentiated | 14% Simple 30% Suprane Proprietary Aseptic & Terminally Vials & Ampoules $1.9B Sterilized Premixes 43% 2017 Sales 27% Drug Compounding Market Leader In Differentiated Drug Formulations And D
Slide 7: Baxter Key Capabilities
Baxter Key Capabilities Hospital leadership in key markets; Hospital Channel Strength global presence in over 100 countries Proven Quality And Patient Safety Track Record 80+ years of injectable experience Global Cost-Effective Manufacturing 28 locations produce injectable or inhalation products Pro
Slide 8: Strategic Growth Drivers
Strategic Growth Drivers Portfolio Innovation Market Development Enter Adjacencies ~$550M Capitalize on differentiated Leverage expertise to 2023 New Product Revenue1 develop complex drug delivery platforms formulations Build a broad portfolio in 5 key therapeutic areas Target specific opportunities
Slide 9: Expansion In Key Therapeutic Areas
Portfolio Market Enter Expansion In Key Therapeutic Areas Innovation Development Adjacencies Specialty Care Oncology Cardiovascular Anti-infectives Anesthesia1 Total Molecules +12 +13 +14 +6 +22 +67 Number of Molecules molecules molecules molecules molecules molecules molecules 138 34 36 71 29 28 23
Slide 10: Baxter's Hospital Channel Strength
Portfolio Market Enter Baxter’s Hospital Channel Strength Innovation Development Adjacencies Recent Successful U.S. Premix Launch With 47% Higher Penetration In First 18 Months1 Hospital Leadership Units per Quarter In Key Markets Global Presence In Over 100 Countries Q1 Q2 Q3 Q4 Q5 Q6 Time from Lau
Slide 11: Differentiated Delivery Platforms
Portfolio Market Enter Differentiated Delivery Platforms Innovation Development Adjacencies Generic Differentiated Drug Value for Patients Injectables Delivery Platform and Customers • Existing generic molecules Aseptic Premixes • Reduces risk of medication errors • Molecules coming off Inhalation P
Slide 12: Complex Drug Formulations
Portfolio Market Enter Complex Drug Formulations Innovation Development Adjacencies Emulsions Oxygen Sensitive Liposomes Nanoparticles Proven Ability To Develop Complex Formulations Cytotoxics Lyophilization Cyclodextrins Inhalation Leveraging Expertise In Complex Formulation Technologies To Expand
Slide 13: Transformative Innovation
Transformative Innovation Novel Drug Delivery Drug Delivery Platforms Expertise Innovation to transform the delivery of medication Strong Hospital Selective Biosimilars Target therapeutic areas of Channel Presence Oncology & Supportive Care Opportunities To Meaningfully Alter The Growth Trajectory O
Slide 14: Pharmaceuticals Summary
Pharmaceuticals Summary Portfolio expansion and scaling in key markets deliver growth of 6% - 7% through 20231 Significant hospital channel strength drives penetration and accelerates share gains Track record of quality and patient safety enables supply continuity and customer satisfaction R&D capab
Slide 15: References
References Baxter Addressable Market (Slide 4) 1) Portfolio expansion over 5 year time period (2018-2023). Subject to regulatory approvals. Generic Injectables Market Dynamics (Slide 5) 1) Sources: NCBI, IMS, Pharmaceutical Commers; FDA, Orange Book, The FDA Group, Pharmaceutical Online January 2018
Slide 16: 2018 Investor Conference
— 2018 Investor Conference a